Ipriflavone: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
No edit summary
Line 1: Line 1:


{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457127710
| IUPAC_name = 7-isopropoxy-3-phenyl-4''H''-chromen-4-one
| image = ipriflavone.png
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|ipriflavone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 35212-22-7
| ATC_prefix = M05
| ATC_suffix = BX01
| PubChem = 3747
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 80BJ7WN25Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01338
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 165790
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 3616


{{Drugbox
 
| IUPAC_name        = 3-phenyl-7-propan-2-yloxychromen-4-one
<!--Chemical data-->
| image            = ipriflavone.png
| C=18 | H=16 | O=3  
| CAS_number        =
| molecular_weight = 280.318 g/mol
| ATC_prefix        =
| synonyms = <small>3-phenyl-7-propan-2-yloxychromen-4-one</small>
| ATC_suffix        =
| smiles            = CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3
| PubChem          = 3747
| InChI            = 1/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
| DrugBank          =
| InChIKey          = SFBODOKJTYAUCM-UHFFFAOYAK
| C=18|H=16|O=3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| molecular_weight = 280.318 g/mol
| StdInChI         = 1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
| bioavailability  =  
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| protein_bound    =  
| StdInChIKey      = SFBODOKJTYAUCM-UHFFFAOYSA-N
| metabolism        =  
| elimination_half-life =  
| excretion        =  
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=
| legal_AU         = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US          =  <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status      =  
| routes_of_administration =  
}}
}}
{{SI}}
 
'''Ipriflavone''' is a synthetic [[isoflavone]] which is used to maintain bone density and to prevent [[osteoporosis]] in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the [[osteoclast]]s (bone-eroding cells), allowing the [[osteoblast]]s (bone-building cells) to build up bone mass.
'''Ipriflavone''' is a synthetic [[isoflavone]] which may be used to inhibit bone resorption,<ref name="pmid9263610">{{cite journal |doi=10.1007/s002239900378 |title=In Vitro and in Vivo effects of ipriflavone on bone formation and bone biomechanics |year=1997 |last1=Civitelli |first1=R. |journal=Calcified Tissue International |volume=61 |pages=S12–4 |pmid=9263610}}</ref> maintain bone density and to prevent [[osteoporosis]] in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the [[osteoclast]]s (bone-eroding cells), possibly allowing the [[osteoblast]]s (bone-building cells) to build up bone mass.
 
A clinical trial reported in 2001 that it was ''not'' effective in prevention or treatment of osteoporosis.<ref>{{cite journal |pages=1482–8 |doi=10.1001/jama.285.11.1482 |title=Ipriflavone in the Treatment of Postmenopausal Osteoporosis: A Randomized Controlled Trial |year=2001 |last1=Alexandersen |first1=P. |journal=JAMA |volume=285 |issue=11 |pmid=11255425 |last2=Toussaint |first2=A |last3=Christiansen |first3=C |last4=Devogelaer |first4=JP |last5=Roux |first5=C |last6=Fechtenbaum |first6=J |last7=Gennari |first7=C |last8=Reginster |first8=JY |author9=Ipriflavone Multicenter European Fracture Study }}</ref>
 
A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on [[otosclerosis]] sufferers.<ref>{{cite journal |pmid=1343452 |year=1992 |last1=Sziklai |first1=I |last2=Komora |first2=V |last3=Ribári |first3=O |title=Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis |volume=33 |issue=1–2 |pages=101–7 |journal=Acta chirurgica Hungarica}}</ref>
 
==References==
{{Reflist}}


==External links==
==External links==
*[http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/ipr_0147.shtml Ipriflavone] at PDR Health
*[http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/ipr_0147.shtml Ipriflavone] at PDR Health


[[Category:Flavonoids]]
{{Drugs for treatment of bone diseases}}
{{Bisphosphonates}}
{{isoflavone}}
[[Category:Endocrinology]]
 
[[Category:Isoflavones]]
[[Category:Phenol ethers]]
 


{{WikiDoc Help Menu}}
{{musculoskeletal-drug-stub}}
{{WikiDoc Sources}}

Revision as of 13:15, 13 April 2015

Ipriflavone
Clinical data
Synonyms3-phenyl-7-propan-2-yloxychromen-4-one
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H16O3
Molar mass280.318 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Ipriflavone is a synthetic isoflavone which may be used to inhibit bone resorption,[1] maintain bone density and to prevent osteoporosis in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass.

A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis.[2]

A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers.[3]

References

  1. ↑ Civitelli, R. (1997). "In Vitro and in Vivo effects of ipriflavone on bone formation and bone biomechanics". Calcified Tissue International. 61: S12–4. doi:10.1007/s002239900378. PMID 9263610.
  2. ↑ Alexandersen, P.; Toussaint, A; Christiansen, C; Devogelaer, JP; Roux, C; Fechtenbaum, J; Gennari, C; Reginster, JY; Ipriflavone Multicenter European Fracture Study (2001). "Ipriflavone in the Treatment of Postmenopausal Osteoporosis: A Randomized Controlled Trial". JAMA. 285 (11): 1482–8. doi:10.1001/jama.285.11.1482. PMID 11255425.
  3. ↑ Sziklai, I; Komora, V; Ribári, O (1992). "Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis". Acta chirurgica Hungarica. 33 (1–2): 101–7. PMID 1343452.

External links

Template:Drugs for treatment of bone diseases Template:Isoflavone


Template:Musculoskeletal-drug-stub

Retrieved from "https://www.wikidoc.org/index.php?title=Ipriflavone&oldid=1086405"